sNDA Submitted to FDA for Gedatolisib in PIK3CA-Mutant, HR+/HER2-Negative ...

Reports

2

Domains carrying it

2

First reported

26 August 2026

Latest report

27 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 26 August 2026sNDA Submitted to FDA for Gedatolisib in PIK3CA-Mutant, HR+/HER2-Negative ...onclive.com
2. 27 August 2026sNDA for Gedatolisib Submitted to FDA in PIK3CA-Mutant Breast Cancercancernetwork.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Grants Accelerated Approval to a New Breast Cancer Treatment8 reports · 7 domains · 5 September 2026
• FDA Approves Ziihera Regimens in First-Line HER2+ Advanced GEA14 reports · 10 domains · 2 September 2026
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer59 reports · 51 domains · 5 September 2026
• AstraZeneca's Breast Cancer Pill Gets Approval From the FDA5 reports · 5 domains · 5 September 2026
• Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally ...4 reports · 4 domains · 25 August 2026
• US FDA approves Replimune's skin cancer drug15 reports · 14 domains · 10 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• sNDA for Gedatolisib Submitted to FDA in PIK3CA-Mutant Breast Cancercancernetwork.com · 27 August 2026
• sNDA Submitted to FDA for Gedatolisib in PIK3CA-Mutant, HR+/HER2-Negative ...onclive.com · 26 August 2026